Piper Jaffray Downgrades Genomic Health To Neutral, $25 PT

March 23, 2011 7:44 AM | 7 seconds read |
Piper Jaffray has downgraded Genomic Health, Inc. GHDX from Overweight to Neutral and has established a $25 price target.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: DowngradesPrice TargetAnalyst RatingsBiotechnologyGenomic HealthHealth CarePiper Jaffray
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!